nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
About This CME Activity
|
|
|
2010 |
7 |
2 |
p. 58- 1 p. |
artikel |
2 |
Ampullary cancer: review and clinical update
|
Chan, Melissa |
|
2010 |
7 |
2 |
p. 61-66 6 p. |
artikel |
3 |
Angioimmunoblastic T-cell lymphoma presenting as extensive psoriasis: a case report and discussion
|
Zaiden, Robert |
|
2010 |
7 |
2 |
p. 90-92 3 p. |
artikel |
4 |
Hereditary breast and ovarian cancer testing: integration and outcomes within community oncology practices
|
Eisenbraun, Ann |
|
2010 |
7 |
2 |
p. 75-81 7 p. |
artikel |
5 |
Hereditary cancer: the challenges are pedigree interpretation, risk assessment, and management—not genetic testing
|
Fowler, Eric |
|
2010 |
7 |
2 |
p. 82-83 2 p. |
artikel |
6 |
Incidence of acute phase adverse events following denosumab or intravenous bisphosphonates: results from a randomized, controlled phase II study in patients with breast cancer and bone metastases
|
Campbell-Baird, Cynthia |
|
2010 |
7 |
2 |
p. 85-89 5 p. |
artikel |
7 |
Intraperitoneal chemotherapy for ovarian cancer
|
Robinson, William R. |
|
2010 |
7 |
2 |
p. 67-72 6 p. |
artikel |
8 |
IP chemotherapy for ovarian cancer: is the questionable benefit worth the added toxicity?
|
Chu, Christina S. |
|
2010 |
7 |
2 |
p. 73-74 2 p. |
artikel |
9 |
ITP in Patients Infected With Hepatitis C Virus: Practicing With Howard Liebman, MD
|
|
|
2010 |
7 |
2 |
p. 58-59 2 p. |
artikel |
10 |
Mass screening: when does it make sense?
|
Streiner, David L. |
|
2010 |
7 |
2 |
p. 93-95 3 p. |
artikel |
11 |
Pazopanib in advanced renal cell carcinoma
|
Abraham, Jame |
|
2010 |
7 |
2 |
p. 56-57 2 p. |
artikel |
12 |
RACs are a reality: what now?
|
|
|
2010 |
7 |
2 |
p. 96- 1 p. |
artikel |
13 |
Staying on top of it all
|
Henry, David H. |
|
2010 |
7 |
2 |
p. 55- 1 p. |
artikel |
14 |
The list of novel agents for advanced renal cell carcinoma expands yet again
|
Choueiri, Toni K. |
|
2010 |
7 |
2 |
p. 57- 1 p. |
artikel |